Cesnicabtagene autoleucel

Phase II, multicenter, open-label, prospective, non-randomized study to evaluate the safety and efficacy of ARI0002h, a CAR-T cell against BCMA, for the initial treatment of patients with primary plasma cell leukaemia

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma